PDPL

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Parenteral Drugs (India) Limited has informed the Exchange that the Company has appointed Mr. Yogesh Khakre as the Company Secretary & Compliance Officer of the Company w.e.f. April 01, 2013 and Ms. Archna Agar has submitted her resignation from the post of Company Secretary and Compliance Officer w.e.f. March 31, 2013. Consequently, she has ceased to be the designated Compliance Officer of the Company w.e.f. that date.

Mahaganpati Investment private Limited has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Commercial Services Pvt ltd has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

PDPL Securities Pvt ltd has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

PDPL Holdings Private Limited has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rajratan Exports Private Limited has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

MVG Mercantile Private Limited has submitted to the Exchange vide its letter dated April 08, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has informed the Exchange that the one of the wholly owned subsidiaries of the Company M/s. Goa Formulations Limited has executed an agreement with M/s.Fresenius Kabi India Private Limited to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs.200 Cr. and the agreement has become binding on the parties. Further, Parenteral Drugs (India) Limited has also accorded its consent to the transaction as the holding company.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2012.

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 09, 2012, has issued and allotted 70,37,898 0% Redeemable Preference Shares of Rs.10/- each at a premium of Rs. 51.40 per share out of which 52,11,000 preference shares are fully paid up and 18,26,898 preference shares shall be partly paid up which shall be made fully paid up within a period of 18 months from the date of allotment.

Parenteral Drugs (India) Limited has informed the Exchange that the Corporate Debt Restructuring Cell, Mumbai vide letter dated November 08, 2012 has conveyed that the final restructuring package for the company has been approved by CDR EG. Necessary steps pursuant to the approval are being taken by the lenders.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2012.

Parenteral Drugs (India) Limited has submitted to the exchange a copy of the Proceedings of the Annual General Meeting of the Company held on September 29, 2012.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 26, 2012 to September 29, 2012 for the purpose of Annual General Meeting.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2012.

Parenteral Drugs (India) Limited has informed the Exchange vide its letter dated June 11, 2012 that "the Lead Banker of the Company State Bank of India and other consortium bankers have, after due consideration, forwarded the Corporate Debt Restructuring proposal of the Company to the CDR cell for consideration."

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Parenteral Drugs (India) Limited has informed the Exchange that the Company has decided to publish Audited Financial Results for the year ended/quarter ended March, 2012 instead of Un-audited Financial Results for the quarter ended March 31, 2012. The Audited Financial Results shall be published within 60 days from end of last quarter (i.e. on or before May 30, 2012).

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2011.

Price movement : Significant price movement has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has vide its letter inter-alia stated, "We would like to submit that with regard to the perfomance of the Company and internal price sensitive factors (which do not include any change in Govt. policies), the same are being submitted to you from time to tim

Rajratan Exports Private Limited has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mahaganpati Investment Private Limited has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of Minutes of the Annual General Meeting of the members of the Company held on September 30, 2011.

Parenteral Drugs (India) Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 30, 2011.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 27, 2011 to September 30, 2011 for the purpose of Annual General Meeting.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of statement of appropriations under Clause 20 of the Listing Agreement.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the members of the Company held on September 30, 2010.

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 15, 2010 inter-alia has issued and allotted 64,66,708 fully paid up bonus equity shares on capitalization of the profits of the Company in the ratio of 1 (one) bonus shares for every 3 (three) equity shares held by the members of the Company.

Parenteral Drugs (India) Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 30, 2010.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed on September 15, 2010 for the purpose of Annual General Meeting, Payment of Dividend, if approved by the members of the Company and Bonus Issue.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of statement of appropriations under Clause 20 of the Listing Agreement.

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 2, 2010 has recommended a dividend of Rs. 2.00 per equity share for the year ended March 31, 2010, subject to approval of the shareholders of the Company, at the ensuing Annual General Meeting of the Company.

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 02, 2010 declared the Bonus issue in the ratio of 1 (one) fully paid up Bonus Shares for every 3 (three) fully paid up equity shares held by the members of the Company.